Spectral AI, Inc. (NASDAQ:MDAI) submitted a De Novo 510k application to the FDA for its DeepView System, using multispectral imaging and AI to predict burn wound healing. The system, designed for emergency departments and burn centers, provides same-day and week-long injury assessments for early treatment decisions, aiming for FDA clearance.
Company Chairman Dr. J. Michael DiMaio views the FDA submission for DeepView as a significant step towards improving patient outcomes. The project, supported by federal funding since 2013, has received multiple development contracts. Spectral AI specializes in predictive diagnostics with its flagship product, the DeepView System, undergoing regulatory review.
While acknowledging the investment potential of MDAI, certain AI stocks may offer greater upside potential with less downside risk. For an undervalued AI stock benefiting from Trump-era tariffs and the onshoring trend, explore the best short-term AI stock. Spectral AI continues to innovate in the medical technology sector, backed by ongoing public-sector support.
Read more at Yahoo Finance: Spectral AI (MDAI) Submits FDA Application for DeepView Burn Assessment System